# PT-141 Benefits Reported in Research

> PT-141 benefits reported in research: improved sexual desire and reduced distress in women with HSDD, a central mechanism, and what the access literature shows — cited.

The benefits the trials and reviews actually recorded — and the honest limits around them.

## The short version

The PT-141 benefits that hold up are the ones measured in controlled trials, and they are specific. In premenopausal women with HSDD — distressing low sexual desire — bremelanotide improved sexual desire and reduced the distress attached to it over 24 weeks, and those gains lasted for up to a year [3][4]. The benefit is central: it works on the brain's desire circuitry, not on blood flow, which is what makes it a different tool than erection medicines [1]. The catch is that the approved benefit applies to one group only; benefits claimed for men, postmenopausal women, or performance are off-label or still under study [7][14]. Below we lay out the documented benefits, read them through the access lens, and recommend nothing to anyone.

## The benefit the regulator recognized

The core PT-141 benefits are the two the FDA reviewed: improved sexual desire (FSFI-desire +0.35, P<.001) and reduced desire-related distress (FSDS-DAO item 13 −0.33, P<.001) over 24 weeks in the RECONNECT Phase 3 trials of 1,267 premenopausal women with HSDD [3]. A 52-week extension in 684 women showed the benefit was sustained without new safety signals [4], and a 2025 meta-analysis found improvement across the total Female Sexual Function Index plus the desire and arousal subscales [15]. These are modest, real, and specific — and, by independent accounts, small enough that their everyday significance is debated [3].

## Why the benefit is central, not vascular

The mechanistic benefit is what sets PT-141 apart: it acts in the brain. A placebo-controlled brain-imaging study in 31 women with HSDD found an MC4R agonist increased sexual desire for up to 24 hours and changed how the brain processed erotic stimuli [5], and preclinical work showed selective enhancement of desire-driven sexual behavior in female rats [2]. Because the action is central rather than on vascular smooth muscle, the benefit is about desire and motivation, not mechanical blood flow [1]. This is also why it does not raise testosterone and is not a PDE-5 inhibitor [1].

## Benefits under investigation

Some claimed benefits remain investigational. Early dose-escalation studies in men with erectile dysfunction produced a dose-dependent erectile response [1], and a manufacturer began a Phase 2 study in 2024 combining bremelanotide with an erection medicine for male erectile dysfunction [14]. The central melanocortin system is also a target for metabolic disease, and high-frequency dosing produced caloric-intake and body-weight effects in early research [11][7]. None of these is an approved benefit; we label them investigational because the regulatory record does.

## Access as a benefit lens

For a sexual-health therapy, access is part of the benefit story — a treatment helps no one who cannot reach a clinician. Published work has described how remote evaluation operates in sexual medicine and the access considerations clinicians weigh [8], and a 2025 multi-country study tracked how telemedicine for sexual medicine grew during the pandemic [13]. We summarize that literature as context for how access works, not as a service we offer; this site dispenses nothing and prescribes nothing.

---

A plain-clinical reading room on bremelanotide — the trials, the label, and how access works, with no dose recommended to anyone.